Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals covering all disciplines from bench to bedside. QUVIVIQ™ (daridorexant) is a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern. Idorsia has strong partners to maximise the value of its portfolio, a promising in‑house development pipeline, and a specialised drug discovery engine focused on small‑molecule drugs that can change the treatment paradigm for many patients.
Head of Global Supply Chain